GlassScriptPhysician profile
Shoban A Dave
NPI 1558377317
$2,083.34
in general payments reported to CMS, 2019-2025
16 companies · $716 in 2025
The $716 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $12.94 · 2021: $15.04 · 2022: $12.92 · 2023: $36.19 · 2024: $1,031 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.84 |
| Education | $114.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $702.06 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $568.33 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $313.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $91.15 | 2024 | |
| Genentech USA, INC. | $84.48 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $71.50 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $47.24 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.84 | 2024 | Eohilia |
| Lilly USA, LLC | $37.19 | 2024-2025 | Ebglyss |
| Kaleo, INC. | $28.37 | 2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $26.10 | 2019 | |
| Optinose US, INC. | $18.65 | 2024 | |
| Biocryst US Sales Co., LLC | $17.88 | 2024 | Orladeyo |
| Alk-Abello, INC | $12.92 | 2022 | |
| Organon LLC | $12.69 | 2025 | Vtama |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoban Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.